Patient-Reported Outcomes From a Phase 3 Study of Givinostat in Patients With Duchenne Muscular Dystrophy

To report an adverse event or product complaint, please contact us by phone at +1.833.582.4312

Home
Resources
- Posters & Presentations
- Publications
Products
- Duvyzat Prescribing Information
- Frequently Asked Questions
Research
- Rare Disease Pipeline
- Medical Research, Grants and Sponsorships
Contact Us

Home
Resources
- Posters & Presentations
- Publications
Products
- Duvyzat Prescribing Information
- Frequently Asked Questions
Research
- Rare Disease Pipeline
- Medical Research, Grants and Sponsorships
Contact Us

Laura McAdam, Federica Alessi, Nuria Muelas, Liesbeth De Waele, Katiana Gruppioni, Sara Cazzaniga, Paolo Bettica, Craig M. Zaidman

Home
Medical Information Request
Research
Contact Us

*This is a website intended for US healthcare professionals only.

ITF Therapeutics © 2026 All Rights Reserved.
M-GIV-US-0062 08/2026

Sitemap
Cookie Policy
Privacy Policy
Terms + Conditions - ITF Therapeutics LLC, a division of Italfarmaco S.p.A.

Confirm you are a US Healthcare Professional

You are about to enter a site that is for United States (US) healthcare professionals only. By selecting “Yes” below, you certify that you are a healthcare professional residing in the US and that you wish to proceed to the healthcare professionals only site.

Please note that the information provided within this site is for educational purposes only and is not intended to be promotional or to provide medical advice.

YES

Talk with an MSL

First Name(Required)

Last Name(Required)

Institution

Degree or Specialty

Preferred Method of Contact(Required)

Phone

Phone(Required)

Email(Required)

Zip Code(Required)

State(Required)

Topic of Discussion/Question

Sunshine Act(Required)

* I certify that I am a licensed US healthcare professional and that this medical information request was unsolicited by ITF Pharmaceutical personnel. I understand that any articles provided to me in response to my request may be reportable as a transfer of value under the US Physician Payment Sunshine Act or applicable state transparency laws.